| Literature DB >> 27214828 |
A Galli1, L Giordano1, D Sarandria1, D Di Santo1, M Bussi1.
Abstract
Several therapeutic options are used for treatment of early stage glottic carcinoma (Tis/T1/T2): open partial laryngectomy (OPL), radiotherapy and CO2 laser-assisted endoscopic surgery. Laser surgery has gradually gained approval in the management of laryngeal cancer. We present our experience in endoscopic laser surgery for early stage glottic carcinomas. This was a retrospective analysis of 72 patients with T1-T2 glottic cancer treated with laser cordectomy between 2006 and 2012. All patients had at least a 36-month follow-up period. Percentages for disease-specific survival, disease-free survival (DFS) and laryngeal preservation rates were 98.6%, 84.7% and 97.2% respectively. Considering neoplastic features that could predict long-term oncological outcome, tumoural involvement of anterior commissure and pathological staging (pT) significantly correlate with local recurrence (p = 0.021 and p = 0.035) and with a lowered DFS (p = 0.017 and p = 0.023). Other variables such as clinical staging, type of cordectomy, involvement of other structures and surgical margin status showed no significant impact on oncological endpoints. CO2 laser surgery is a reliable technique for T1-T2 glottic cancer considering oncological outcomes. The recurrence rate seems to be affected by involvement of anterior commissure and pT stage. © Copyright by Società Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale, Rome, Italy.Entities:
Keywords: CO2 laser-surgery; Early stage; Endoscopic cordectomy; Glottic carcinoma; Laryngeal cancer; Larynx
Mesh:
Year: 2016 PMID: 27214828 PMCID: PMC4977004 DOI: 10.14639/0392-100X-643
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Recurrence rates and disease-free survival (DFS; mean ± standard deviation) stratified according to variables of interest.
| Variable | No. of cases | Recurrence rates | p value | DFS in months (mean ± SD) | p value | |
|---|---|---|---|---|---|---|
| cT | cT1a | 61 | 8/61 (13.1%) | 0.230 | 33.7 ± 6.8 | 0.198 |
| cT1b-cT2 | 11 | 3/11 (27.3%) | 29.7 ± 11.4 | |||
| pT | pTis-pT1a | 61 | 7/61 (11.5%) | 0.035 | 34.0 ± 6.3 | 0.023 |
| pT1b-pT2 | 11 | 4/11 (36.4%) | 27.7 ± 12.1 | |||
| Anterior commissure | Free | 53 | 5/53 (9.4%) | 0.021 | 34.3 ± 6.2 | 0.017 |
| Involved | 19 | 6/19 (31.6%) | 29.7 ± 10.4 | |||
| Supraglottis | Free | 63 | 8/63 (12.7%) | 0.108 | 33.6 ± 7.0 | 0.094 |
| Involved | 9 | 3/9 (33.3%) | 29.0 ± 11.2 | |||
| Vocal muscle | Free | 55 | 8/55 (14.5%) | 0.756 | 33.2 ± 7.7 | 0.760 |
| Involved | 17 | 3/17 (17.6%) | 32.6 ± 8.0 | |||
| Cordectomy | Type I | 9 | 2/9 (22.2%) | 0.561 | 34.3 ± 4.3 | 0.600 |
| Type II | 14 | 3/14 (21.4%) | 31.3 ± 10.2 | |||
| Type III | 20 | 3/20 (15.0%) | 32.7 ± 8.3 | |||
| Type IV | 12 | 0/12 (0%) | 36.0 ± 0 | |||
| Type V | 17 | 3/17 (17.6%) | 32.2 ± 8.8 | |||
| Superficial (type I, II, III) | 43 | 8/43 (18.6%) | 0.339 | 32.6 ± 8.3 | 0.353 | |
| Deep (type IV, V) | 29 | 3/29 (10.3%) | 33.8 ± 6.9 | |||
| Resection margin status | Free | 38 | 4/38 (10.5%) | 0.250 | 34.8 ± 3.8 | 0.193 |
| Single superficial positive | 13 | 1/13 (7.7%) | 33.9 ± 7.5 | |||
| Deep positive | 7 | 2/7 (28.6%) | 28.0 ± 13.7 | |||
| Unassessable (surgical artifacts) | 14 | 4/14 (28.6%) | 30.0 ± 10.6 |
Chi-squared test;
Log-rank test;
cT = clinical staging; pT = pathological staging
Fig. 1.Bar chart showing 3-year recurrence rates according to pT stage (p = 0.035).
Fig. 2.Bar chart showing 3-year recurrence rates according to anterior commissure involvement (p = 0.021).
Fig. 3.Kaplan-Meier survival curves stratified according to pT stage (p = 0.023).
Fig. 4.Kaplan-Meier survival curves stratified according to anterior commissure involvement (p = 0.017).